Summary
Forty-five postmenopausal osteoporotic women with at least one osteoporotic vertebral crush fracture were randomized into three treatment groups. Each patient was on calcitonin, 50 U, on alternate days for 2 weeks monthly (350 U/month), and 500 mg/day oral calcium supplementation. In group II, this therapy was supplemented with phosphate (750 mg/day), and in group III, norandrostenolone decanoate (50 mg/month) was added to the calcitonin + calcium therapy. Bone mineral content, by single photon absorptiometry, of the radius midshaft and distal site (3 cm), as well as the lumbar and metacarpal radiomorphometrical indices were estimated semiannually. The therapeutic trial lasted 36 months except in the phosphate supplementation group, where, due to unfavorable results, treatment was discontinued after 24 months. Calcitonin practically prevented further bone loss for 24 months even in this relatively small and intermittent dosage. Phosphate supplementation was without benefit; however, according to the majority of the examined parameters, combination of calcitonin with the anabolic steroid norandrostenolone decanoate extended efficacy up to 36 months. This latter combination seems to be a promising, relatively inexpensive therapeutic regimen in the treatment of established postmenopausal osteoporosis.
Similar content being viewed by others
References
Chesnut CH (1984) Synthetic salmon calcitonin, diphosphonates and anabolic steroids in the treatment of postmenopausal osteoporosis. In: Christiansen C, Arnaud CD, Nordin BEC, Parfitt AM, Peck WA, Riggs BL (eds) Osteoporosis. Copenhagen, pp 549–555
Riggs BL, Hodgson SF, O'Fallon WM, Chao EYS, Wahner HW, Muhs JM, Cedel SL, Melton LJ III (1990) Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802–809
Watts NB, Harris ST, Genant HK, Wasnick RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC III, Yanover MJ, Mysiw J, Kohse L, Rao MB, Steiger P, Richmond B, Chestnut CH III (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73–79
Barnett E, Nordin BEC (1961) Radiological assessment of bone density. Br J Radiol 34:683–698
Krasznai I, Lakatos P, Horváth Cs, Holló I (1987) Precision of estimation of bone mineral content by single and dual photon absorptiometry in longitudinal studies. J Nucl Med 26:212–213 (Congress ed)
Zséli J, Szücs J, Steczek K, Szathmári M, Kollin É, Horváth Cs, Guoth M, Holló I (1983) Decreased calcitonin reserve in accelerated postmenopausal osteoporosis. Horm Metab Res 17:696–697
Holló I, Boross M, Szücs J (1971) Sex hormone deficiency and calcitonin sensitivity. Lancet II:1205–1206
Holló I, Fehér T, Szücs J (1970) Serum dehydroepiandrosterone, androsterone and cortisol level in primary postmenopausal and other type osteoporosis. Acta Med Acad Sci Hung 27:155–160
Marshall DH, Crilly RG, Nordin BEC (1977) Plasma androstendione and oestrone levels in normal and osteoporotic postmenopausal women. Br Med J 2:1177–1179
Holló I, Boross M, Szücs J (1975) Effect of sex hormone deficiency on calcitonin-induced hypocalcaemia. Acta Gerontol 5:609–616
Holló I, Szücs J, Steczek K (1971) Effect of norandrostenolone decanoate on calcium tolerance curves of patients with primary osteoporosis. Endokrinologie 58:326–330
Szücs J, Holló I, Guoth M (1984) Calcitonin in pathological postmenopausal osteoporosis: theory and practice. In: Christiansen C, Arnaud CD, Nordin BEC, Parfitt AM, Peck WA, Riggs BL (eds) Osteoporosis. Copenhagen pp 693–694
Szücs J, Holló I, Guoth M, Horváth Cs, Horváth K, Kollin É (1986) Long-term intermittent, small dose calcitonin in menopausal osteoporosis. In: Delmas PD, Meunier PJ, Cohn DV (eds) IXth ICCRH and Bone Metabolism (abstract 874) Nice, France
Hirsch PF (1968) Enhancement of hypocalcemic activity of thyrocalcitonin by inorganic phosphate. In: Symposium on thyrocalcitonin and the C-cells. Heineman Ltd, London p 11
Raisz LG, Dietrich JW, Maina D (1975) Effects of phosphate on bone formation and resorption in tissue culture. In: Avioli L, Bordier Ph, Fleisch H, Massry S, Slatopolsky E (eds) Phosphate metabolism kidney and bone. Nouvelle Imprimerie Fournié, Toulouse pp 213–221
Rasmussen H, Bordier Ph, Marie P, Auquier L, Eisinger JB, Kuntz D, Caulin F, Argemi B, Gueris J, Julien A (1980) Effect of combined therapy with phosphate and calcitonin on bone volume in osteoporosis. Metab Bone Dis Rel Res 2:107–111
Kanis JA (1984) Treatment of osteoporotic fracture. Lancet I:27–33
Itoi E, Sakurai M, Mizunashi K, Sato K, Kasama F (1990) Long-term observations of vertebral fractures in spinal osteoporotics. Calcif Tissue Int 47:202–208
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Szücs, J., Horváth, C., Kollin, É. et al. Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine. Calcif Tissue Int 50, 7–10 (1992). https://doi.org/10.1007/BF00297289
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00297289